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Abstract
There has been concern about the performance of CURB-65 in older patients with community-acquired pneumonia (CAP) and that
younger patients who subsequently die are initially misclassiﬁed as having non-severe CAP. The purpose of this study was to evaluate
the effect of age on the performance of CURB-65. We analysed data prospectively, collected in two UK hospitals. Patients were strati-
ﬁed into four age cohorts. Mortality in each cohort was then stratiﬁed by CURB-65 score. Sensitivity, speciﬁcity, positive predictive
value (PPV), negative predictive value (NPV) and area under the receiver operating curve (AUROC) were calculated. Four hundred and
twenty-eight patients were included. Misclassiﬁcation of patients who subsequently died as non-severe CAP patients (CURB-65 score of
£2) increased with increasing age (from 3% in the <65-year cohort to 27% in those aged >85 years). There were no deaths (0/105) in
those aged <65 years who had a CURB-65 score of 0 or 1. At the British Thoracic Society cut-off for severe CAP (CURB-65 score of
‡3), CURB-65 performed best in 16–64-year-olds (PPV 0.4, NPV 0.97). The AUROC was signiﬁcantly higher for the <65-year cohort in
comparison with older patients (0.93 vs. 0.7, p <0.05). Clinicians should interpret the CURB-65 score with care in older patients
referred to hospital with CAP. In those aged <65 years, however, CURB-65 appears to be able to identify a cohort of patients
(CURB-65 score of 0 or 1) with very low mortality.
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Introduction
Community-acquired pneumonia (CAP) is a leading cause of
death and morbidity worldwide [1–3]. Major national and
specialist society guidelines support the use of severity
assessment in guiding clinical decisions regarding the site of
care and level of medical intervention required [1–3]. To aid
severity assessment in CAP, a number of severity scores
have been validated to predict the need for intensive-care
unit (ICU) admission and mortality [4–6]. CURB-65 was
developed and validated by Lim et al. [4], and has subse-
quently been shown to have moderate discrimination for the
prediction of mortality in CAP [7–9]. The score is calculated
by assigning one point for each of the following criteria that
are present at assessment: new confusion, urea >7 mM,
respiratory rate ‡30/min, systolic blood pressure <90 mmHg
or diastolic blood pressure £60 mmHg, and age ‡65 years. It
is the recommended severity score in the CAP guidelines of
the British Thoracic Society (BTS) [1]. The 2007 Infectious
Diseases Society of America/American Thoracic Society
guidelines also suggest CURB-65 as an appropriate score to
help clinicians in making site-of-care decisions [3].
Older age has long been recognized as a risk factor for
mortality in CAP [10]. A recent large epidemiological study
of patients hospitalized with CAP in England and Wales
showed an increase in mortality from 6% in those aged
<65 years to 47% in those aged >85 years; 70% of patients
were aged ‡65 years [11]. In contrast, in the original deriva-
tion/validation study of Lim et al., 58% were aged ‡65 years
[4]. In subsequent studies that have tested the performance
of CURB-65, the age characteristics of the studied cohorts
have varied considerably, with the proportion of patients
aged ‡65 years ranging from 55% to 78% [7–9]. Buising et al.
demonstrated that the performance characteristics of CURB-
65 change when patients aged >90 years, nursing home resi-
dents and those considered to be unsuitable for aggressive
management are removed from analyses [12]. Other authors
have reﬂected concern that CURB-65 will sometimes classify
younger patients who are subsequently admitted to the ICU
ª2009 The Authors
Journal Compilation ª2009 European Society of Clinical Microbiology and Infectious Diseases
ORIGINAL ARTICLE 10.1111/j.1469-0691.2009.02908.x
and/or die as being at low or intermediate risk (i.e. a CURB-
65 score of 0–2) [13]. Variation in the performance of
CURB-65 with age has not been formally assessed. This is
important because signiﬁcant variation of performance with
age may affect how clinicians interpret CURB-65 scores and
the weight given to scores in inﬂuencing management deci-
sions. The primary objective of this study was to assess how
the performance characteristics of CURB-65 change with
increasing age in adult patients referred to hospital for
assessment of CAP.
Materials and Methods
Participants
The study was performed using data collected for the evalua-
tion of a quality improvement project. Collection of the data
was approved by both Tayside University Hospitals NHS
Trust’s medical ethics committee and the Caldicot guardian.
This cohort has been described in detail previously [8,14].
The study was performed in two UK hospitals, a 1000-bed
teaching hospital and a 500-bed district general hospital. At
both sites, patients were referred to the acute medical
assessment units (AMAUs). Patients were then discharged to
be treated as outpatients, admitted to the AMAU for a short
period, or admitted to a general medical ward.
Patients were identiﬁed prospectively by review of AMAU
records in the periods 1 November 2001 to 31 April 2002
and 1 November 2002 to 31st April 2003. A wide range of
potential CAP presentations were reviewed (e.g. pleuritic
chest pain, shortness of breath, and fever). Patients were
included if they were receiving an antibiotic for a lower
respiratory tract infection and had either a new inﬁltrate on
the chest radiograph or had been clinically diagnosed as hav-
ing CAP by a specialist registrar or consultant physician.
Patients were excluded if they were aged <16 years, taking
immunosuppressive drugs (long-term (>2 weeks) predniso-
lone (or equivalent) of ‡15 mg or immunosuppressive ther-
apy such as methotrexate, azathioprine, or mycophenalate),
human immunodeﬁciency virus-positive, neutropenic (neutro-
phil count of <1.0 · 109/L), or had aspiration, hypostatic or
hospital-acquired pneumonia (as diagnosed and documented
by the admitting medical team), or progressive malignancy.
For the purposes of this study, patients were also excluded
if one or more of the CURB-65 criteria had not been
recorded on admission to hospital, if 30-day mortality was
not available, or if the diagnosis was changed prior to dis-
charge from hospital or death. We included patients with a
do-not-resuscitate order only if they were otherwise being
actively managed.
For each patient, the CURB-65 score was calculated from
the ﬁrst recorded set of observations after they had arrived
at hospital, wherever this occurred. Severe CAP was deﬁned
according to the BTS deﬁnition (i.e. a CURB-65 score of 3
or more). Mortality at 30 days after admission to hospital
was established prospectively if the patient died in hospital,
and retrospectively, using a hospital computer database, if
the patient died after discharge. Demographic, clinical and
outcome data were recorded on a piloted data collection
sheet and checked before being double-entered into an
Epi-Info database (CDC, Atlanta, and WHO, Geneva).
Statistical analyses
Included patients were stratiﬁed into four age-based cohorts:
16–64 years, 65–74 years, 75–84 years, and ‡85 years.
Descriptive statistics are presented as numbers and percent-
ages. The demographic and clinical characteristics of the age
cohorts were compared using the chi-squared for trend test.
We also analysed the statistical associations between the
patient characteristics of age cohorts and 30-day mortality
by non-parametric tests (chi-squared test or Fisher’s exact
test).
For each age cohort, 30-day mortality was stratiﬁed by
CURB-65 score. The sensitivity, speciﬁcity, positive predic-
tive value (PPV), negative predictive value (NPV) and area
under the receiver operating curve (AUROC) of CURB-65
were calculated for each cohort [15,16]. For each AU-
ROC, 95% CIs are presented. For each age cohort, the
AUROC was statistically compared to a null hypothesis
AUROC of 0.5 (i.e. using CURB-65 to predict mortality
would be no better than guessing). All statistical analyses
were performed using SPSS (version 12). For all analyses,
a two-sided p-value of <0.05 was considered to be statisti-
cally signiﬁcant.
Results
The case notes and drug charts of 1393 patients with pre-
sentations that might have represented CAP were reviewed.
Of these, 503 patients were included in our original study
[14]; the reasons for exclusion are shown in Table S1. Of
these 503 patients, 75 (15%) had an exclusion criterion for
this study. The demographic and clinical characteristics of
included and excluded patients are described in Table 1. The
results of univariate analyses for the associations between
patient characteristics and 30-day mortality are shown in
Table 2. In general, all of the CURB-65 criteria were
signiﬁcantly associated with mortality across the age cohorts
and overall. In those aged <65 years, there were no deaths
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in the 101 patients who had a serum urea £7 mM as com-
pared with six deaths (19%) in the 31 patients who had a
serum urea >7 mM (Table 2).
The proportion of patients with a CURB-65 score of 3 or
more increased from 4% (5/132) in those aged <65 years to
57% (43/76) in those aged ‡85 years (Table 1). Mortality in
patients with a CURB-65 score of 0–2 increased from 3% to
27% with increasing age (Table 2). In those aged <65 years,
there were no deaths in the 105 patients who had a CURB-
65 score of 0 or 1. There were four (18%) deaths, however,
in the 22 patients who had a CURB-65 score of 2. At the
BTS cut-off for the diagnosis of severe CAP (CURB-65 score
of ‡3), the 16–65-year-cohort had the highest PPV (0.40)
and NPV (0.97); see Table 3. The performance of CURB-65
as measured by AUROC is shown in Table 4. The AUROC
for all age cohorts was signiﬁcantly greater than the null
hypothesis, except in those aged ‡85 years. Further analyses
were performed with the exclusion of nursing and residential
home patients (n = 70). Although the AUROC for the
cohort aged ‡85-year cohort increased to 0.67 from 0.59,
other performance characteristics were otherwise similar for
all age cohorts and did not alter our conclusions (Table 4).
Discussion
Our results suggest that the performance of CURB-65 changes
with increasing age in two main ways. First, the proportion of
patients who were misclassiﬁed as having non-severe CAP by
the BTS deﬁnition (a CURB-65 score of 0–2), but who subse-
quently died, increased with increasing age. With the excep-
tion of the cohort aged ‡85 years, this was mostly due to
deaths occurring in those with a CURB-65 score of 2. The
BTS guidelines recommend that patients with a CURB-65
score of 2 should initially receive treatment in hospital, but
may be suitable for an early discharge once objective clinical
improvement has occurred [1]. Clinicians should note that
deaths occurred in patients with a CURB-65 score of 2 regard-
less of age, and that some patients may therefore require a
higher level of intervention than might be expected.
TABLE 1. Characteristics of patients stratiﬁed by age
Age (years) 16–64 65–74 75–84 85+ All Excluded patients v2 for trenda, p-value
Number 132 92 128 76 428 75 –
Age >65 years – – – – – 61 (81) –
Demographics, no. (%)
Male 67 (51) 40 (44) 64 (50) 30 (40) 201 (47) 34 (45) NS
Living in own home 128 (97) 80 (87) 104 (81) 46 (61) 358 (84) 52 (69) <0.001
Living alone 24 (18) 32 (35) 58 (45) 40 (53) 154 (36) 30 (40) <0.001
Clinical characteristics, no. (%)
Pulse ‡125/min 14 (11) 13 (14) 10 (8) 6 (8) 43 (10) 5 (7) NS
RR ‡30/min 28 (21) 24 (26) 27 (21) 13 (17) 92 (22) 5/26 (19) NS
Systolic BP <90 mmHg 9 (7) 7 (8) 6 (5) 3 (4) 25 (6) 6 (8) NS
Diastolic BP £60 mmHg 33 (25) 20 (22) 33 (26) 18 (24) 104 (24) 22 (29) NS
Oximetry <92% 29 (22) 30 (33) 55 (43) 27 (36) 141 (33) 19/74 (26) 0.004
Urea >7 mM 31 (24) 58 (63) 98 (77) 59 (78) 246 (58) 48 (64) <0.001
New confusion 11 (8) 29 (32) 61 (48) 30 (40) 131 (31) 29/68 (43) <0.001
C-reactive protein >50mg/L 98 (74) 67 (73) 80 (63) 48 (63) 293 (69) 48/69 (70) 0.06
Bilateral CXR changes 17 (13) 16 (17) 25 (20) 11 (15) 69 (16) 7 (9) NS
Chronic illness (‡1) 66 (50) 69 (75) 89 (70) 53 (70) 277 (65) 56 (75) 0.002
Chronic heart disease 14 (11) 37 (40) 47 (37) 36 (47) 134 (31) 27/74 (36) <0.001
Chronic lung disease 46 (35) 46 (50) 41 (32) 14 (18) 147 (34) 26 (35) 0.06
Diabetes mellitus 5 (4) 15 (16) 22 (17) 9 (12) 51 (12) 12 (16) 0.02
Other chronic illness 17 (13) 14 (15) 23 (18) 14 (18) 68 (16) 12 (16) NS
Temperature >38C 45 (34) 29 (32) 33 (26) 13 (17) 120 (28) 13 (17) 0.007
WCC >12 · 109/L 81 (61) 51 (55) 58 (45) 43 (57) 233 (54) 39 (52) NS
Severity assessment, no. (%)
CURB65 = 0 61 (46) NA NA NA 61 (14) – –
CURB65 = 1 44 (33) 15 (16) 16 (12) 8 (10) 83 (19) – –
CURB65 = 2 22 (17) 37 (40) 38 (30) 25 (33) 122 (29) – –
CURB65 = 3 4 (3) 27 (29) 42 (33) 34 (45) 107 (25) – –
CURB65 = 4 1 (0.7) 10 (11) 30 (23) 8 (10) 49 (11) – –
CURB65 = 5 NA 3 (3) 2 (1.5) 1 (1.3) 6 (1) – –
Initial antimicrobial regimen, no. (%)
B b-lactam plus macrolide 59 (45) 42 (46) 74 (58) 32 (42) 207 (48) 29 (39) –
N b-lactam plus macrolide 48 (36) 30 (33) 31 (24) 23 (30) 132 (31) 22 (29) –
b-Lactam monotherapy 10 (8) 10 (11) 11 (9) 10 (13) 41 (10) 12 (16) –
Macrolide monotherapy 2 (1.5) 2 (2) 6 (5) 2 (3) 12 (3) 3 (4) –
Others 13 (10) 8 (9) 6 (5) 9 (12) 36 (8) 9 (12) –
Outcomes, no. (%)
In-hospital deaths 5 (4) 13 (14) 33 (26) 27 (36) 78 (18) 7 (9) <0.001
Transferred to ICU 9 (7) 4 (4) 1 (0.8) 0 (0) 14 (3) 0 (0) 0.001
Thirty-day mortality 6 (5) 13 (14) 34 (27) 26 (34) 79 (19) 11 (15) <0.001
B, broad spectrum (b-lactam/b-lactamase inhibitors and second-generation and third-generation cephalosporins); BP, blood pressure; ITU, intensive-care unit; N, narrower
spectrum (benzylpenicillin and amoxycillin); NA, not applicable; NS, not statistically signiﬁcant; RR, respiratory rate; WCC, white cell count.
aAcross age cohorts.
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Reassuringly, and in contrast to the commonly held anec-
dotal view that seriously ill young adults with CAP some-
times have a low CURB-65 score, no deaths occurred in the
105 patients who were aged <65 years and had a CURB-65
score of 0 or 1. This is consistent with the results of previ-
ous studies, and conﬁrms that CURB-65 can be used safely
in those aged <65 years to identify patients suitable for out-
patient therapy or an early discharge from hospital [4,7,9].
Serum urea of >7 mM was the characteristic most strongly
associated with mortality in those aged <65 years (all who
died in this age group had a serum urea of >7 mM), and may
therefore be a useful cardinal warning sign in this cohort of
patients, regardless of the overall CURB-65 score. In con-
trast, respiratory rate was not signiﬁcantly associated with
mortality in the 16–65-year cohort. In patients aged between
65 and 84 years, it may still be safe to use a CURB-65 score
of 1 to identify those suitable for outpatient therapy or an
early discharge from hospital, but clinicians should take
account of other important factors, such as social circum-
stances and chest radiograph appearance. This should be a
focus for future research.
Second, at the BTS cut-off for severe CAP (a CURB-65
score of 3 or more), with the exception of sensitivity, calcu-
lated performance characteristics deteriorated with increas-
ing age. Perhaps unsurprisingly, CURB-65’s ability to identify
a low-risk group of patients or predict mortality in those
aged ‡85 years was poor. In those aged <65 years, a cut-off
of 2 or more for severe CAP may be more appropriate
(than a cut-off of 3 or more), as this provided higher sensi-
tivity and NPV, albeit with lower speciﬁcity and PPV. A cut-
off of 2 or more would have reduced the misclassiﬁcation of
non-severe CAP to zero. Myint et al. previously suggested
that the urea, diastolic blood pressure and confusion criteria
of CURB-65 may not be good discriminators in the elderly
[17,18]. In our study, a urea level of >7 mM and new confu-
sion were signiﬁcantly more common in the elderly, but not
TABLE 2. Mortality stratiﬁed by age and patient characteristics (pvalues for univariate analyses are shown under the descrip-
tive statistics)
Age (years)a
16–64 ‡65 All
Number 132 296 428
Characteristic, no. (%) Yes No Yes No Yes No
Male 3/67 (5) 3/65 (5) 32/134 (24) 41/162 (25) 35/201 (17) 44/227 (19)
p 1.0 p 0.8 p 0.6
Living in own home 5/128 (4) 1/4 (25) 52/230 (23) 21/66 (32) 57/358 (16) 22/70 (31)
p 0.2 p 0.13 p 0.002
Living alone 2/24 (8) 4/108 (4) 28/130 (21) 45/164 (27) 30/154 (20) 49/272 (18)
p 0.3 p 0.2 p 0.7
Oral route available on admission 2/101 (2) 4/29 (14) 39/227 (17) 33/63 (52) 41/328 (13) 37/92 (40)
p 0.02 p <0.001 p <0.001
Pulse ‡125/min 1/14 (7) 5/118 (4) 9/29 (31) 64/267 (24) 10/43 (23) 69/385 (18)
p 0.5 p 0.4 p 0.4
Respiratory rate ‡30/min 1/27 (4) 5/105 (5) 23/64 (36) 50/232 (21) 24/91 (26) 55/337 (16)
p 1.0 p 0.02 p 0.03
Systolic BP <90 mmHg 2/9 (22) 4/123 (3) 9/16 (56) 64/280 (23) 11/25 (44) 68/403 (17)
p 0.05 p 0.003 p 0.002
Diastolic BP £60 mmHg 4/33 (12) 2/99 (2) 19/71 (27) 54/225 (24) 23/104 (22) 56/324 (17)
p 0.03 p 0.6 p 0.3b
Oximetry <92% 3/29 (10) 3/100 (3) 33/112 (29) 40/181 (22) 36/141 (26) 43/281 (15)
p 0.13b p 0.16 p 0.01
Urea >7 mM 6/31 (19) 0/101 (0) 67/215 (31) 6/81 (7) 73/246 (30) 6/182 (3)
p <0.001 p <0.001 p <0.001
New confusion 3/11 (27) 3/121 (3) 43/120 (36) 30/176 (17) 46/131 (35) 33/297 (11)
p 0.008 p <0.001 p <0.001
C-reactive protein >50mg/L 5/98 (5) 1/22 (5) 50/195 (26) 17/67 (25) 55/293 (19) 18/89 (20)
p 1.0 p 0.9 p 0.8
Bilateral chest radiograph changes 2/17 (12) 4/115 (4) 23/52 (44) 47/239 (20) 25/69 (36) 51/354 (14)
p 0.2 p <0.001 p <0.001
Asthma/COPD 1/46 (2) 5/86 (6) 15/101 (15) 58/194 (30) 16/147 (11) 63/280 (23)
p 0.7 p 0.004 p 0.003
Comorbidity 3/66 (5) 3/66 (5) 51/211 (24) 23/85 (27) 53/277 (19) 26/151 (17)
p 1.0 p 0.6 p 0.7
Temperature <36C 1/7 (14) 5/125 (4) 11/33 (33) 62/263 (24) 12/40 (30) 67/388 (17)
p 0.3 p 0.2 p 0.05
White cell count <4.0 or >12 · 109/L 5/84 (6) 1/48 (2) 41/154 (27) 32/141 (23) 46/238 (19) 33/189 (18)
p 0.4 p 0.4 p 0.6
BP, blood pressure; COPD, chronic obstructive pulmonary disease.
aIncreasing age was signiﬁcantly associated with mortality in the overall cohort by univariate analyses (p <0.001).
bUnivariate logistic regression using the continuous variable gave a p-value £0.05.
CMI Parsonage et al. CURB-65 and increasing age 861
ª2009 The Authors
Journal Compilation ª2009 European Society of Clinical Microbiology and Infectious Diseases, CMI, 15, 858–864
more strongly associated with mortality, than in younger
patients. In contrast, diastolic blood pressure was more
strongly associated with mortality in younger patients.
Teramoto et al. showed that a higher cut-off for age
(>80 years vs. >65 years) was more strongly associated with
mortality in lower respiratory tract infection [19]. This is in
keeping with our ﬁndings and those of Trotter et al. [11].
Only one of 204 (0.5%) patients aged >75 years was
admitted to the ICU, as compared with 13 of 224 (6%) aged
<75 years. This may represent entirely appropriate clinical
decision-making, but could also represent a healthcare
inequality. We have previously published qualitative data in
which one respondent reﬂected on his experiences of the
ICU refusing to take older patients who he considered to be
treatable [20]. In the same study, older patients were signiﬁ-
cantly less likely to be given guideline adherent antibiotics.
These ﬁndings may be speciﬁc to the UK, but require further
investigation.
Our study also has implications for antibiotic stewardship
and guideline recommendations for antibiotic therapy in
CAP. The results show that most patients (96%) aged
<65 years who were admitted to hospital with CAP had a
CURB-65 score of 0–2 (i.e. non-severe). In contrast, over
half (53%) of those aged >65 years had a CURB-65 score of
3 or more. It is well recognized that the risk of Clostridium
difﬁcile-associated diarrhoea and infection due to resistant
pathogens is higher in older patients [21]. The BTS guidelines
recommend the use of an intravenous broad-spectrum b-lac-
tam agent (co-amoxiclav or a second-generation or third-
generation cephalosporin) plus an intravenous macrolide for
the initial treatment of CAP with a CURB-65 score of 3 or
more [2]. Respiratory ﬂuoroquinolones are offered as alter-
natives. In contrast, the recommendation for patients with a
CURB-65 score of 0–2 is either amoxycillin or a macrolide,
alone or in combination. Exposure to second-generation or
third-generation cephalosporins and quinolones is a recog-
nized risk factor for Clostridium difﬁcile-associated diarrhoea
[21]. Monnet et al. showed that the consumption of cephalo-
sporins, macrolides and quinolones was signiﬁcantly associated
with the emergence of methicillin-resistant Staphylococcus
aureus in a UK hospital [22]. If clinicians in the UK are follow-
ing guideline recommendations, therefore, a high propor-
tion of older patients admitted to hospital with CAP will
receive broad-spectrum therapy, although, in our study, the
TABLE 3. Mortality and performance characteristics stratiﬁed by age and CURB-65 score (the deﬁnitions of the performance
characteristics used are provided in Table S2)
CURB-65 score
by age cohort
Thirty-day mortality,
no. (%)
Sensitivity
(95% CI)
Speciﬁcity
(95% CI)
PPV
(95% CI)
NPV
(95% CI)
16–64 years
0 or 1 0/105 (0) 1.0 0.48 0.09 1.0
2 4/22 (18) 1.0 0.83 0.22 1.0
‡3 2/5 (40) 0.33 (0.04–0.78) 0.98 (0.93–0.99) 0.40 (0.05–0.85) 0.97 (0.92–0.99)
65–74 years
1 1/15 (7) 1.0 0 0.14 NC
2 2/37 (5) 0.92 0.22 0.16 0.93
‡3 10/40 (25) 0.77 (0.46–0.95) 0.62 (0.50–0.72) 0.25 (0.13–0.41) 0.94 (0.84–0.99)
75–84 years
1 0/16 (0) 1.0 0 0.27 NC
2 7/38 (18) 1.0 0.17 0.30 1.0
‡3 27/74 (36) 0.79 (0.62–0.91) 0.50 (0.39–0.60) 0.37 (0.25–0.48) 0.87 (0.75–0.95)
>85 years
1 2/8 (25) 1.0 0 0.34 NC
2 7/25 (28) 0.92 0.12 0.35 0.75
‡3 17/43 (40) 0.65 (0.44–0.83) 0.48 (0.34–0.62) 0.40 (0.25–0.55) 0.73 (0.54–0.87)
>65 years
1 3/39 (8) 1.0 0 0.25 0
2 16/100 (16) 0.96 0.16 0.27 0.92
‡3 54/157 (34) 0.74 (0.62–0.83) 0.54 (0.47–0.60) 0.34 (0.27–0.42) 0.86 (0.79–0.91)
All ages
0 or 1 3/144 (2) 1.0 0 0.18 NC
2 20/122 (16) 0.96 0.40 0.27 0.98
‡3 56/162 (35) 0.71 (0.59–0.80) 0.70 (0.64–0.74) 0.35 (0.27–0.42) 0.91 (0.87–0.94)
NC, not calculable; NPV, negative predictive value; PPV, positive predictive value.
TABLE 4. Area under receiver operating curves (AUROC)
stratiﬁed by age and residential status
Age
cohort
(years)
All patients
With nursing/residential
home patients excluded
AUROC 95% CI p-valuea AUROC 95% CI p-valuea
16–64 0.93 0.88–0.98 <0.001 0.95 0.91–1.00 <0.001
65–74 0.74 0.58–0.90 0.005 0.71 0.55–0.87 0.016
75–84 0.74 0.64–0.83 <0.001 0.70 0.60–0.80 0.001
>85 0.59 0.45–0.73 0.2 0.67 0.50–0.83 0.06
>65 0.70 0.63–0.77 <0.001 0.70 0.62–0.78 <0.001
All ages 0.78 0.73–0.83 <0.001 0.80 0.74–0.85 <0.001
aStatistically signiﬁcant vs. null hypothesis.
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proportion of patients receiving different antibiotic regimens
was similar across the cohorts. Guideline developers should
consider this conundrum when recommending antibiotic
regimens for severe CAP in older patients.
Potential weaknesses of this study
As with all observational studies, our results could have been
affected by bias and/or confounding. As data were originally
collected for a quality improvement study, we used a prag-
matic deﬁnition of CAP. One advantage of this, however, is
that the patients in this cohort are more likely to represent
the patients whom clinicians treat for CAP in real life. It is
important that severity scores are tested in real-life cohorts
as well as in reference standard research cohorts, which
tend to exclude more patients. Although our study included
a relatively large total number of patients, two of our age
cohorts had fewer than 100 patients. Mortality (19%) in our
cohort was higher than reported in some studies (e.g. 9% in
the validation study of Lim et al. [4]). This is likely to be due
to the considerably higher proportion of patients who were
aged >65 years (69% vs. 58%), had a CURB-65 score of 3 or
more (38% vs. 29%), and had cardiovascular disease (32% vs.
18%). The last-mentioned of these is consistent with the
well-described epidemiology of cardiovascular disease in
Scotland [23]. Also, the age-speciﬁc and overall mortality are
similar to those reported by Trotter et al. [11].
In summary, the performance of CURB-65 in predicting
mortality deteriorated with increasing age. In particular, mis-
classiﬁcation of patients who subsequently died as non-severe
CAP patients increased with increasing age. In contrast, in
those aged <65 years and with a CURB-65 score of 0 or 1,
mortality was zero. Clinicians should be cautious about how
they interpret CURB-65 scores in older patients.
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